1Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Japan
2Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
3Department of General Internal Medicine, Kawasaki Medical School, Japan
4Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan
5Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
6Department of Internal Medicine, Saga Medical School, Saga University, Saga, Japan
7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan
8Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan.
9Department of Gastroenterology, JA Hiroshima Kouseiren General Hospital, Japan
10Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
11Department of Gastroenterology, Suita City Hospital, Osaka, Japan
12Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
13Department of Molecular Biochemistry & Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
14Hepatology Center, Saiseikai Suita Hospital, Japan
*Corresponding author:Zhong Chen, Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. No. 300 Yishan Road, Shanghai 200233, P.R.China
Submission: February 11, 2020Published: February 20, 2020
ISSN : 2578-0263Volume3 Issue3
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. The grade of hepatic fibrosis is known to be closely associated with over-all or liver-related mortality in NAFLD. In order to detect early stage of hepatocellular carcinoma (HCC), it is essential to identify advanced hepatic fibrosis in NAFLD. To avoid invasive liver biopsies, several modalities have developed for evaluating hepatic fibrosis, including elastography (FibroScan and magnetic resonance elastography) and noninvasive tests (NITs) such as fibrosis-4 index and NAFLD fibrosis score. Patients with type 2 diabetes is twice at higher risk for incident HCC compared to the non-diabetic population. Although type 2 diabetes is also associated with fibrosis progression of NAFLD, the precise prevalence of advanced hepatic fibrosis in type 2 diabetes remains unknown. To detect or prevent the development of HCC in type 2 diabetes, mining patients with advanced fibrosis (stage 3/4) is important. It is estimated that approximately 17% of patients with type 2 diabetes receiving liver biopsies had advanced fibrosis. Population-based data are essential because of excluding selection bias. In this review, we review estimated prevalence of advanced hepatic fibrosis in patients with type 2 diabetes by using non-invasive elastography.
Keywords: Diabetes, Hepatic fibrosis, Elastography, Fibroscan, Magnetic resonance elastography
Abbreviations: NAFLD: Nonalcoholic Fatty Liver Disease; HCC: Hepatocellular Carcinoma; NITs: Noninvasive Tests; ARFI: Acoustic Radiation Force Impulse; MRE: Magnetic Resonance Elastography